Drug Trial Radar · NCT07908524
MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
290
Planned (sponsor's estimate)
Start
Dec 14, 2026
Primary completion
Jun 29, 2032
Study completion Jun 29, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer/androgen pathway modulator refractory (mCRPC/APMR). Current treatment for mCRPC includes chemotherapy, such as docetaxel. Chemotherapy is medicine that works to destroy cancer cells or stop them from growing. In this trial, researchers want to learn if giving sacituzumab tirumotecan (sac-TMT) alone or with other treatments can treat mCRPC. Sac-TMT is a trial medicine that is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells. Opevesostat is another trial medicine designed to block the body from making steroid hormones that cause the cancer cells to grow. The goals of this trial are to learn: * How many participants have the cancer respond (gets smaller or goes away) to the trial treatments * About the safety of the trial treatments and if participants tolerate the treatments. Tolerate means participants will receive the trial treatments unless they need to stop it due to health problems.
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
Sacituzumab tirumotecanBiological
IV infusion
Rescue medicationDrug
Participants receiving sac-TMT may be administered the following rescue medications according to the approved product: granulocyte colony-stimulating factor, histamine-1 receptor antagonist, histamine-2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent, and steroid mouthwash (dexamethasone or equivalent).
DocetaxelDrug
IV infusion
PrednisoneDrug
Oral administration
OpevesostatDrug
Oral administration
Abiraterone acetateDrug
Oral administration
EnzalutamideDrug
Oral administration
PrednisoloneDrug
Oral administration
FludrocortisoneDrug
Oral administration
DexamethasoneDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy Phase: Objective Response Rate (ORR)Time frame: Up to approximately 66 months
- Efficacy Phase: Number of Participants Who Experience at Least One Adverse Event (AE)Time frame: Up to approximately 66 months
- Efficacy Phase: Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 66 months
- Safety Lead-In (Combination Arms Only): Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)Time frame: Up to approximately 28 days
- Safety Lead-In (Combination Arms Only): Number of Participants Who Experience at Least One AETime frame: Up to approximately 66 months
- Safety Lead-In (Combination Arms Only): Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 66 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.